Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hans Tesch

Showing results (31-40 of 171) with videos related to

Pageof 18
Sort By:
Journal of Cancer Research and Clinical Oncology|November 22, 2021
Cytoreductive treatment in real life: a chart review analysis on 1440 patients with polycythemia veraCarl C Crodel, Kathleen Jentsch-Ullrich, Marcel Reiser, et al.
World Journal of Urology|June 10, 2016
Systemic therapy in metastatic renal cell carcinomaJens Bedke, Thomas Gauler, Viktor Grünwald, et al.
The New England Journal of Medicine|June 13, 2003
Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's diseaseVolker Diehl, Jeremy Franklin, Michael Pfreundschuh, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 27, 2017
Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendationsMatti Aapro, Ralph Boccia, Robert Leonard, et al.
Annals of Hematology|March 13, 2024
Spotlight on the real-world treatment of CML pts in Germany: a retrospective survey in private oncology practicesGeorg-Nikolaus Franke, Gunnar Loewe, Marcel Reiser, et al.
Anticancer Research|July 2, 2010
Prevalence of CA 27.29 in primary breast cancer patients before the start of systemic treatmentBrigitte Rack, Christian Schindlbeck, Julia Jückstock, et al.
Anticancer Research|March 16, 2016
First-line Bevacizumab-containing Therapy for HER2-negative Metastatic Breast Cancer: Final Results from a Prospective German StudyAndreas Schneeweiss, Frank Förster, Hans Tesch, et al.
Future Oncology (London, England)|February 28, 2024
Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myelomaLuciano J Costa, Thomas W LeBlanc, Hans Tesch, et al.
Breast Cancer Research and Treatment|August 11, 2010
Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio studyJens Huober, Gunter von Minckwitz, Carsten Denkert, et al.
Journal of Geriatric Oncology|September 6, 2015
Trastuzumab in the treatment of elderly patients with early breast cancer: Results from an observational study in GermanyPeter Dall, Gertrud Lenzen, Thomas Göhler, et al.
Pageof 18

Showing results (31-40 of 171) with videos related to

Sort By:
Pageof 18
Journal of Cancer Research and Clinical Oncology|November 22, 2021
Cytoreductive treatment in real life: a chart review analysis on 1440 patients with polycythemia veraCarl C Crodel, Kathleen Jentsch-Ullrich, Marcel Reiser, et al.
World Journal of Urology|June 10, 2016
Systemic therapy in metastatic renal cell carcinomaJens Bedke, Thomas Gauler, Viktor Grünwald, et al.
The New England Journal of Medicine|June 13, 2003
Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's diseaseVolker Diehl, Jeremy Franklin, Michael Pfreundschuh, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 27, 2017
Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendationsMatti Aapro, Ralph Boccia, Robert Leonard, et al.
Annals of Hematology|March 13, 2024
Spotlight on the real-world treatment of CML pts in Germany: a retrospective survey in private oncology practicesGeorg-Nikolaus Franke, Gunnar Loewe, Marcel Reiser, et al.
Anticancer Research|July 2, 2010
Prevalence of CA 27.29 in primary breast cancer patients before the start of systemic treatmentBrigitte Rack, Christian Schindlbeck, Julia Jückstock, et al.
Anticancer Research|March 16, 2016
First-line Bevacizumab-containing Therapy for HER2-negative Metastatic Breast Cancer: Final Results from a Prospective German StudyAndreas Schneeweiss, Frank Förster, Hans Tesch, et al.
Future Oncology (London, England)|February 28, 2024
Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myelomaLuciano J Costa, Thomas W LeBlanc, Hans Tesch, et al.
Breast Cancer Research and Treatment|August 11, 2010
Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio studyJens Huober, Gunter von Minckwitz, Carsten Denkert, et al.
Journal of Geriatric Oncology|September 6, 2015
Trastuzumab in the treatment of elderly patients with early breast cancer: Results from an observational study in GermanyPeter Dall, Gertrud Lenzen, Thomas Göhler, et al.
Pageof 18